In the crowded biotech landscape, most companies chase obvious targets. Acelot is betting its future on the ones everyone else ignores—using a 'new approach to challenging targets' that could redefine early-stage drug discovery.

"They're not building another AI drug discovery platform—they're building a precision engine for targets others can't crack."

Their tech stack reveals telling priorities: Squarespace for presence, but Stimulus and jQuery for functional depth. The 50% direct traffic (versus 27% organic) suggests a strong referral network—likely from industry conferences and partner deals rather than broad marketing. This is how biotech actually works: reputation, not SEO.

• Targeted traffic: 93.2% from undefined markets (likely US/EU pharma hubs)
• Low digital footprint: Only 2,528 monthly visits shows they're not playing the content game
• Keyword strategy: Ranking for 'acelot' (440 volume) and niche terms like 'vidhu' (3,840 volume)
• Team efficiency: 21 employees generating $3.3M revenue = $157K per employee